Confronting the Clinical and Economic Burden of Atopic Dermatitis: Managed Care Considerations on the Role of New and Emerging Therapies

A continuing medical education activity provided by NAMCP and AAMCN

This activity is an archive from the live session from the 2022 Spring Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from August 1, 2022, to August 1, 2023
 

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.
 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by an educational grant from
Incyte

Description:
Atopic dermatitis is a common chronic inflammatory skin disease characterized by persistent itching that can severely affect quality of life. This condition evolves from a combination of skin barrier defects and immune-mediated responses involving activated T-helper cells and related cytokines. Our improved understanding of the pathophysiology underlying atopic dermatitis is resulting in the development of targeted therapies for children and adult patients with this disease. There are approximately 17.8 million people with eczema or atopic dermatitis in the United States. Older treatments adequately care for patients with atopic dermatitis, but have shown problems with sustained efficacy in patients with eczema or atopic dermatitis. Fortunately for patients with this disease, several new treatments have recently become available, including JAK inhibitors, that have shown improved efficacy and safety, offering patients the potential for improved outcomes and quality of life. This activity will focus on new and emerging potential therapies, how clinicians can potentially integrate them into the treatment paradigm, what managed care professionals and payors need to know about these new options, and information on the mechanisms of action of these agents. With so many new options becoming potentially available in the management of atopic dermatitis, it is critical that physician medical directors, payers, pharmacy directors, pharmacists, nurse case managers and other HCPs are updated on the safety and efficacy data on these emerging options, possible strategies for implementing them into the treatment paradigm, and key points that managed care professionals need to know, which will ultimately improve patient outcomes.

Upon completion of this activity, participants will be able to:

• Explore the unmet clinical and economic needs in atopic dermatitis (AD) and the impact of inadequately treated disease on physical and mental health, quality of life, costs and work productivity

• Examine atopic dermatitis including the Janus kinase signal transducer and activator of transcription (JAK-STAT) pathophysiology, range of clinical symptoms/severity, and challenges with current standard therapies

• Describe the immunopathogenic mechanisms of AD and the rationale for targeting the relevant cytokines, including IL-13

• Compare and contrast efficacy and safety profiles of novel therapeutics in AD, including IL-13 antagonists and JAK inhibitors, in a range of patient populations

• Analyze the evolving role of new and emerging IL-13 antagonists and JAK inhibitors in the management of AD

• Review strategies for anticipating, recognizing, and managing adverse events of newer therapy in patients with AD outcomes
  
   

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)^TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in nursing continuing professional development.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This activity is supported by an educational grant from
Incyte

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue